Literature DB >> 25777533

Differential expression of TOX by skin-infiltrating T cells in Sézary syndrome and erythrodermic dermatitis.

Stephanie E Boonk1, Fatma Çetinözman1, Maarten H Vermeer1, Patty M Jansen2, Rein Willemze1.   

Abstract

BACKGROUND: The histopathologic differentiation between Sézary syndrome (SS) and erythrodermic dermatitis may be extremely difficult. In this immunohistochemical study, it was investigated if thymocyte selection-associated high mobility group box protein (TOX) and C-MYC can be used as additional diagnostic markers to differentiate between SS and erythrodermic dermatitis.
METHOD: Paraffin-embedded skin biopsies from 15 SS patients and 17 erythrodermic dermatitis patients were stained and scored for TOX or C-MYC expression.
RESULTS: Strong nuclear staining for TOX in more than 50% of skin-infiltrating T cells was observed in 13 of 15 (87%) SS cases, whereas erythrodermic dermatitis cases showed weak nuclear staining in 11-50% (median: 25%) of the T cells; strong nuclear staining as found in SS was never observed in erythrodermic dermatitis. No significant differences in C-MYC expression between SS and erythrodermic dermatitis were found. In most patients of both groups, percentages of C-MYC positive-cells varied between less than 10 and 25% of skin-infiltrating T cells.
CONCLUSION: Our results suggest that strong expression of TOX in more than 50% of skin-infiltrating T cells in erythrodermic skin is a useful marker in the differentiation between SS and erythrodermic dermatitis, whereas staining for C-MYC does not contribute to differential diagnosis.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  C-MYC; Sézary syndrome; TOX; erythroderma; immunohistochemistry

Mesh:

Substances:

Year:  2015        PMID: 25777533     DOI: 10.1111/cup.12490

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  7 in total

Review 1.  Sézary Syndrome: Clinical and Biological Aspects.

Authors:  Rebecca Kohnken; Stephanie Fabbro; Justin Hastings; Pierluigi Porcu; Anjali Mishra
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

2.  CD164 identifies CD4+ T cells highly expressing genes associated with malignancy in Sézary syndrome: the Sézary signature genes, FCRL3, Tox, and miR-214.

Authors:  Bernice M Benoit; Neha Jariwala; Geraldine O'Connor; Landon K Oetjen; Timothy M Whelan; Adrienne Werth; Andrea B Troxel; Hélène Sicard; Lisa Zhu; Christopher Miller; Junko Takeshita; Daniel W McVicar; Brian S Kim; Alain H Rook; Maria Wysocka
Journal:  Arch Dermatol Res       Date:  2016-10-20       Impact factor: 3.017

Review 3.  Proteomic Approaches to Biomarker Discovery in Cutaneous T-Cell Lymphoma.

Authors:  Alexandra Ion; Iris Maria Popa; Laura Maria Lucia Papagheorghe; Cristina Lisievici; Mihai Lupu; Vlad Voiculescu; Constantin Caruntu; Daniel Boda
Journal:  Dis Markers       Date:  2016-10-16       Impact factor: 3.434

4.  Genetic rearrangements result in altered gene expression and novel fusion transcripts in Sézary syndrome.

Authors:  Katarzyna Iżykowska; Grzegorz K Przybylski; Claudia Gand; Floriane C Braun; Piotr Grabarczyk; Andreas W Kuss; Karolina Olek-Hrab; Armando N Bastidas Torres; Maarten H Vermeer; Willem H Zoutman; Cornelis P Tensen; Christian A Schmidt
Journal:  Oncotarget       Date:  2017-06-13

5.  Proteomic Profiling Change and Its Implies in the Early Mycosis Fungoides (MF) Using Isobaric Tags for Relative and Absolute Quantification (iTRAQ).

Authors:  Mengyan Zhu; Yong Li; Cheng Ding; Jiaqi Wang; Yangyang Ma; Zhao Li; Xiaoyan Zhang; Ping Wang
Journal:  Biomed Res Int       Date:  2020-11-23       Impact factor: 3.411

6.  TOX expression in cutaneous B-cell lymphomas.

Authors:  Anne M R Schrader; Patty M Jansen; Rein Willemze
Journal:  Arch Dermatol Res       Date:  2016-05-14       Impact factor: 3.017

7.  Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.

Authors:  Jingkai Xu; He Huang; Shangshang Wang; Yanzhen Chen; Xueli Yin; Xuejun Zhang; Yaohua Zhang
Journal:  Arch Dermatol Res       Date:  2019-11-01       Impact factor: 3.017

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.